534 related articles for article (PubMed ID: 29306730)
21. The metabolic syndrome is associated with more aggressive prostate cancer.
Ozbek E; Otunctemur A; Dursun M; Sahin S; Besiroglu H; Koklu I; Erkoc M; Danis E; Bozkurt M
Asian Pac J Cancer Prev; 2014; 15(9):4029-32. PubMed ID: 24935591
[TBL] [Abstract][Full Text] [Related]
22. Comparison of clinical outcomes between upgraded pathologic Gleason score 3 + 4 and non-upgraded 3 + 4 prostate cancer among patients who are candidates for active surveillance.
Jo JK; Hong SK; Byun SS; Lee SE; Oh JJ
World J Urol; 2015 Nov; 33(11):1729-34. PubMed ID: 25809876
[TBL] [Abstract][Full Text] [Related]
23. Predictors of biochemical recurrence after Retzius-sparing robot-assisted radical prostatectomy: Analysis of 359 cases with a median follow-up period of 26 months.
Abdel Raheem A; Chang KD; Alenzi MJ; Ham WS; Han WK; Choi YD; Rha KH
Int J Urol; 2018 Dec; 25(12):1006-1014. PubMed ID: 30276864
[TBL] [Abstract][Full Text] [Related]
24. What is the optimal definition of misclassification in patients with very low-risk prostate cancer eligible for active surveillance? Results from a multi-institutional series.
Gandaglia G; Ploussard G; Isbarn H; Suardi N; De Visschere PJ; Futterer JJ; Ghadjar P; Massard C; Ost P; Sooriakumaran P; Surcel CI; van der Bergh RC; Montorsi F; Ficarra V; Giannarini G; Briganti A;
Urol Oncol; 2015 Apr; 33(4):164.e1-9. PubMed ID: 25620154
[TBL] [Abstract][Full Text] [Related]
25. Obesity is associated with risk of progression for low-risk prostate cancers managed expectantly.
Bhindi B; Kulkarni GS; Finelli A; Alibhai SM; Hamilton RJ; Toi A; van der Kwast TH; Evans A; Hersey K; Jewett MA; Zlotta AR; Trachtenberg J; Fleshner NE
Eur Urol; 2014 Nov; 66(5):841-8. PubMed ID: 24954793
[TBL] [Abstract][Full Text] [Related]
26. Radical prostatectomy improves progression-free and cancer-specific survival in men with lymph node positive prostate cancer in the prostate-specific antigen era: a confirmatory study.
Steuber T; Budäus L; Walz J; Zorn KC; Schlomm T; Chun F; Ahyai S; Fisch M; Sauter G; Huland H; Graefen M; Haese A
BJU Int; 2011 Jun; 107(11):1755-61. PubMed ID: 20942833
[TBL] [Abstract][Full Text] [Related]
27. Long-term and pathological outcomes of low- and intermediate-risk prostate cancer after radical prostatectomy: implications for active surveillance.
Meissner VH; Woll M; Ankerst DP; Schiele S; Gschwend JE; Herkommer K
World J Urol; 2021 Oct; 39(10):3763-3770. PubMed ID: 33973043
[TBL] [Abstract][Full Text] [Related]
28. Immediate versus delayed radical prostatectomy: updated outcomes following active surveillance of prostate cancer.
Filippou P; Welty CJ; Cowan JE; Perez N; Shinohara K; Carroll PR
Eur Urol; 2015 Sep; 68(3):458-63. PubMed ID: 26138041
[TBL] [Abstract][Full Text] [Related]
29. Percentage of cancer involvement in positive cores can predict unfavorable disease in men with low-risk prostate cancer but eligible for the prostate cancer international: active surveillance criteria.
Russo GI; Cimino S; Castelli T; Favilla V; Urzì D; Veroux M; Madonia M; Morgia G
Urol Oncol; 2014 Apr; 32(3):291-6. PubMed ID: 24184119
[TBL] [Abstract][Full Text] [Related]
30. Cumulative Cancer Locations is a Novel Metric for Predicting Active Surveillance Outcomes: A Multicenter Study.
Erickson AM; Luzzago S; Semjonow A; Vasarainen H; Laajala TD; Musi G; de Cobelli O; Mirtti T; Rannikko A
Eur Urol Oncol; 2018 Sep; 1(4):268-275. PubMed ID: 31100247
[TBL] [Abstract][Full Text] [Related]
31. Pathological stage distribution in patients treated with radical prostatectomy reflecting the need for protocol-based active surveillance: results from a contemporary European patient cohort.
Seiler D; Randazzo M; Klotz L; Grobholz R; Baumgartner M; Isbarn H; Recker F; Kwiatkowski M
BJU Int; 2012 Jul; 110(2):195-200. PubMed ID: 22093744
[TBL] [Abstract][Full Text] [Related]
32. Prognostic utility of biopsy-derived cell cycle progression score in patients with National Comprehensive Cancer Network low-risk prostate cancer undergoing radical prostatectomy: implications for treatment guidance.
Tosoian JJ; Chappidi MR; Bishoff JT; Freedland SJ; Reid J; Brawer M; Stone S; Schlomm T; Ross AE
BJU Int; 2017 Dec; 120(6):808-814. PubMed ID: 28481440
[TBL] [Abstract][Full Text] [Related]
33. Adverse Pathologic Features at Radical Prostatectomy: Effect of Preoperative Risk on Oncologic Outcomes.
Imnadze M; Sjoberg DD; Vickers AJ
Eur Urol; 2016 Jan; 69(1):143-8. PubMed ID: 25913389
[TBL] [Abstract][Full Text] [Related]
34. Analysis of outcomes after radical prostatectomy in patients eligible for active surveillance (PRIAS).
El Hajj A; Ploussard G; de la Taille A; Allory Y; Vordos D; Hoznek A; Abbou CC; Salomon L
BJU Int; 2013 Jan; 111(1):53-9. PubMed ID: 22726582
[TBL] [Abstract][Full Text] [Related]
35. Effects of pathological upstaging or upgrading on metastasis and cancer-specific mortality in men with clinical low-risk prostate cancer.
Kovac E; Vertosick EA; Sjoberg DD; Vickers AJ; Stephenson AJ
BJU Int; 2018 Dec; 122(6):1003-1009. PubMed ID: 29802773
[TBL] [Abstract][Full Text] [Related]
36. Does Time Spent on Active Surveillance Adversely Affect the Pathological and Oncologic Outcomes in Patients Undergoing Delayed Radical Prostatectomy?
Ahmad AE; Richard PO; Leão R; Hajiha M; Martin LJ; Komisarenko M; Grewal R; Goldberg H; Salem S; Jain K; Oliaei A; Horyn I; Timilshina N; Zlotta A; Hamilton R; Kulkarni G; Fleshner N; Alibhaic SMH; Finelli A
J Urol; 2020 Sep; 204(3):476-482. PubMed ID: 32259466
[TBL] [Abstract][Full Text] [Related]
37. Active Surveillance Versus Radical Prostatectomy in Favorable-risk Localized Prostate Cancer.
Thomsen FB; Røder MA; Jakobsen H; Langkilde NC; Borre M; Jakobsen EB; Frey A; Lund L; Lunden D; Dahl C; Brasso K
Clin Genitourin Cancer; 2019 Aug; 17(4):e814-e821. PubMed ID: 31196798
[TBL] [Abstract][Full Text] [Related]
38. Metabolic syndrome predicts worse perioperative outcomes in patients treated with radical prostatectomy for non-metastatic prostate cancer.
Luzzago S; Palumbo C; Rosiello G; Pecoraro A; Deuker M; Stolzenbach F; Mistretta FA; Tian Z; Musi G; Montanari E; Shariat SF; Saad F; Briganti A; de Cobelli O; Karakiewicz PI
Surg Oncol; 2021 Jun; 37():101519. PubMed ID: 33429324
[TBL] [Abstract][Full Text] [Related]
39. Effects of Initial Gleason Grade on Outcomes during Active Surveillance for Prostate Cancer.
Masic S; Cowan JE; Washington SL; Nguyen HG; Shinohara K; Cooperberg MR; Carroll PR
Eur Urol Oncol; 2018 Oct; 1(5):386-394. PubMed ID: 31158077
[TBL] [Abstract][Full Text] [Related]
40. Early salvage radiation therapy does not compromise cancer control in patients with pT3N0 prostate cancer after radical prostatectomy: results of a match-controlled multi-institutional analysis.
Briganti A; Wiegel T; Joniau S; Cozzarini C; Bianchi M; Sun M; Tombal B; Haustermans K; Budiharto T; Hinkelbein W; Di Muzio N; Karakiewicz PI; Montorsi F; Van Poppel H
Eur Urol; 2012 Sep; 62(3):472-87. PubMed ID: 22633803
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
